84
Participants
Start Date
August 17, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
lufepirsen high dose
Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
Vehicle
Matching vehicle without lufepirsen.
lufepirsen low dose
Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
RECRUITING
Glaukos Investigative Site, Bala-Cynwyd
RECRUITING
Glaukos Investigative Site, Shelby
RECRUITING
Glaukos Investigative Site, Atlanta
RECRUITING
Glaukos Investigative Site, South Miami
RECRUITING
Glaukos Investigative Site, Fort Myers
RECRUITING
Glaukos Investigative Site, Bradenton
RECRUITING
Glaukos Investigative Site, Dothan
RECRUITING
Glaukos Investigative Site, Nashville
RECRUITING
Glaukos Investigative Site, Carmel
RECRUITING
Glaukos Investigative Site, Fraser
RECRUITING
Glaukos Investigative Site, Milwaukee
RECRUITING
Glaukos Investigative Site, Madison
RECRUITING
Glaukos Investigative Site, Kansas City
RECRUITING
Glaukos Investigative Site, Kansas City
RECRUITING
Glaukos Investigative Site, Houston
RECRUITING
Glaukos Investigative Site, San Antonio
RECRUITING
Glaukos Investigative Site, Colorado Springs
RECRUITING
Glaukos Investigative Site, Grand Junction
RECRUITING
Glaukos Investigative Site, Torrance
RECRUITING
Glaukos Investigative Site, Petaluma
RECRUITING
Glaukos Investigative Site, Palisades Park
RECRUITING
Glaukos Investigative Site, Mainz
RECRUITING
Glaukos Investigative Site, München
RECRUITING
Glaukos investigative Site, Messina
RECRUITING
Glaukos Investigative Site, Barcelona
RECRUITING
Glaukos Investigative Site, Madrid
RECRUITING
Glaukos Investigative Site, Seville
RECRUITING
Glaukos Investigative Site, Zaragoza
Lead Sponsor
Glaukos Corporation
INDUSTRY